Emergency Department Clinical Pathway for
Evaluation/Treatment of Children with Anaphylaxis
Related Pathways
|
|
---|---|
CRITERIA 1 |
Acute onset of an illness with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritis or flushing, swollen lip-tongue-uvula) AND AT LEAST ONE OF THE FOLLOWING
|
CRITERIA 2 |
Two or more of the following that occur rapidly after exposure to a LIKELY ALLERGEN for that patient:
|
CRITERIA 3 | Reduced BP after exposure to KNOWN ALLERGEN for that patient |
MD/CRNP/RN Rapid Assessment
- Patient meets clinical criteria for Anaphylaxis listed below:
- ADMINISTER EPINEPHRINE IM IMMEDIATELY
- Repeat dose as clinically indicated q 5-15 minutes
- Assess need for IV access
- ASSESS, MANAGE ABC’S
- Mental status abnormality
- Upper airway obstruction
- Lower airway symptoms
- Circulatory abnormality
- Respiratory Medications
- IV Access, NS bolus as indicated
- Vasopressors
|
||
---|---|---|
Epinephrine Dosing - IM | ||
< 5 kg | 0.01 mg/kg | Epinephrine IM 0.1 mg/mL solution |
5 - 25 kg | 0.15 mg | EpiPen Jr® |
> 25 kg | 0.3 mg | EpiPen® |
Risk Factors for Biphasic Reaction
- History of biphasic or severe reactions
- Progression of / or persistent symptoms
- History of severe asthma
- Hypotension
- Requires > 1 Epinephrine dose
- Requires fluid bolus
- Drug trigger
Reassess patient’s symptoms, PE, VS
Serious Symptoms Resolved with
1 dose of Epinephrine, excluding rash
Consider antihistamine for urticaria
1 dose of Epinephrine, excluding rash
Consider antihistamine for urticaria
- Observe 4 hours from Epinephrine treatment
- Begin Epinephrine auto-injector teaching/video
- Discharge Criteria
- Discharge Medications, Teaching
- Refer to Allergy within 1 month
Risk Factors for Biphasic Reactions
- Consider the use of adjunctive medications:
- Antihistamines
- Corticosteroids
Posted: June, 2006
Last Revised: November 2024
Authors: J. Lee, MD; T. Brown-Whitehorn, MD; N. Tsarouhas, MD; J. Lamaina, RN, MSN; J. Molnar, CRNP; R. Sutton, MD; D. Davis, MD; M. Lewis, CRNP; C. Jacobstein, MD; J. Lavelle, MD; MK. Abbadessa, ACCNS-P;
Last Revised: November 2024
Authors: J. Lee, MD; T. Brown-Whitehorn, MD; N. Tsarouhas, MD; J. Lamaina, RN, MSN; J. Molnar, CRNP; R. Sutton, MD; D. Davis, MD; M. Lewis, CRNP; C. Jacobstein, MD; J. Lavelle, MD; MK. Abbadessa, ACCNS-P;
Evidence
- Biphasic Anaphylaxis: Review of Incidence, Clinical Predictors, and Observation Recommendations
- International consensus on (ICON) anaphylaxis
- Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
- Anaphylaxis — a practice parameter: 2015 Update
- Anaphylaxis - A 2020 Practice Parameter Update, Systematic Review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Analysis
CHOP Programs
Related Links